Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Algae, particularly species like spirulina (Arthrospira platensis) and chlorella, have been investigated for their potential benefits in managing Metabolic Syndrome, a cluster of conditions that increase the risk for heart disease, stroke, and type 2 diabetes. Scientific validation for algae’s use largely comes from preclinical and some clinical studies. Spirulina, for example, has demonstrated hypolipidemic, antihypertensive, and anti-inflammatory effects in animal models and in small-scale human trials. Several randomized controlled trials (RCTs) have found that supplementation with spirulina or chlorella can lead to modest improvements in lipid profiles (reducing LDL cholesterol and triglycerides, increasing HDL cholesterol), blood pressure, fasting blood glucose, and markers of oxidative stress in adults with features of Metabolic Syndrome.

A systematic review and meta-analysis published in Clinical Nutrition (2021) concluded that spirulina supplementation resulted in significant reductions in blood pressure and improvements in lipid levels in individuals at risk for or diagnosed with Metabolic Syndrome. Chlorella has shown similar, though somewhat less robust, results in clinical studies. The mechanisms are thought to involve modulation of lipid metabolism, antioxidant activity, and improvement in insulin sensitivity.

Despite these promising results, most studies were relatively small and short-term, and there is a need for larger, longer-duration RCTs to confirm efficacy and establish optimal dosing. Overall, current evidence supports the potential benefit of algae as an adjunct in the management of Metabolic Syndrome, but it should not replace standard therapeutic approaches.

More about Algae
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Algae

Products containing Algae

Douglas Laboratories THYROMEND™